Pharmaceuticals, Biotechnology and Life Sciences
AstraZeneca today announced that the European Commission (EC) has approved Faslodex (fulvestrant) for certain metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.
AstraZeneca on Monday reported closing two different agreements for certain commercial rights for its drugs, in Europe and worldwide.
AstraZeneca and Chi-Med said on Thursday they kicked off the third phase of clinical testing of their cancer drug.
Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca’s drug Lynparza into a precision medicine for prostate cancer.
AstraZeneca has signed an agreement with Grünenthal for the global rights to Zomig (zolmitriptan), the drug indicated for the acute treatment of migraines and cluster headaches, outside Japan.
Genomic Vision, a company specialized in the development of diagnostic tests (IVD) for the early detection of cancers and genetic diseases and applications for life sciences research (LSR), have entered into a technological collaboration with AstraZeneca in the field of targeting DNA damage response (DDR) for novel anti-cancer treatments strategy.
AstraZeneca has reported top-line results from the Phase IIIb/IV EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial that compared the effect of once-weekly Bydureon (exenatide extended-release) versus placebo, when added to usual type-2 diabetes care, on the risk of MACE, a composite endpoint of CV death, non-fatal myocardial infarction or non-fatal stroke, in adults with type-2 diabetes (T2D) at a wide range of CV risk.
AstraZeneca has entered into an agreement with Recordati S.p.A for the commercial rights to Seloken/Seloken ZOK (metoprolol tartrate and metoprolol succinate respectively) and associated Logimax fixed-dose combination (metoprolol succinate and felodipine) treatments in Europe.
AstraZeneca and its subsidiary MedImmune, have reported positive results for the Phase III PACIFIC trial, a randomised, double-blinded, placebo-controlled multi-centre trial of Imfinzi (durvalumab) as sequential treatment in patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy.
AstraZeneca and its subsidiary MedImmune have reported that tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, did not meet its primary endpoint of a significant reduction in the annual asthma exacerbation rate (AAER) in the overall population of severe, uncontrolled asthma patients, compared with placebo in STRATOS 1, the first of two pivotal Phase III trials.